Real Time Search
CES A80 :
CES HKMI :
CES 120 :
Total Turn.

02096 SIMCERE PHARMA

Closed Add to Porfolio
Key Financial Ratio (Fiscal Year: 12/2022)
Current 1.84X Oper Margin 14.6%
LT Debt/Equity 2.2% Net Margin 14.8%
Total Debt/Equity 21.1% Return on Equity 13.1%
Price/Book 1.83X Return on Assets 8.7%
(HKD 5.500) 2022-122021-122020-122019-122018-12
Net Profit (MHKD) 1,045.821,843.33794.601,121.95835.38
Net Profit Growth (%) -43.3+132.0-29.2+34.3+98.6
Earnings Per Share (HKD) 0.4010.7070.332N/AN/A
Earnings Per Share Growth (%) -43.3+112.8+100.0N/AN/A
Dividend Per Share (HKD) 0.1760.1760.180No dividendNo dividend
P/E* (X) 13.737.7816.56N/AN/A
Yield (%) 3.203.193.28N/AN/A
Dividend Share (%) 43.9024.8754.29N/AN/A
Book NAV (HKD) 3.0042.9962.412N/AN/A
Auditors' Opinion UnqualifiedUnqualifiedUnqualifiedN/AN/A
Remarks:
1. Unqualified = Not Qualified because the financial statements have been fairly presented in accordance with appropriate accounting standards and companies ordinance.
2. Unqualified # = Not Qualified in respect of fundamental uncertainty because of appropriate disclosures.
3. Qualified = Qualified Opinion in respect of limitation in audit scope and/or disclaimer on view given by financial statements and/or disagreement of accounting treatment and/or adverse opinion.
Last Update Time: 2024-03-02 21:40:23

Latest Result

(RMBMn) 2023-06 2022-06 Chg* (%) 2021-06
Cover Period (mths) 6 6 NA 6
Turnover 3,379 2,700 +25.1 2,120
Operating Result 1,535 52.859 +2,804.0 33.845
Associates 0.393 -0.334 -217.7 -14.884
Profit Before Taxation 2,325 52.523 +4,326.6 521.84
Taxation 51.346 -9.398 -646.4 -33.055
Profit /( Loss) After Taxation 2,274 61.921 +3,572.4 554.895
Minority Interests -0.811 -1.863 -56.5 -2.919
Net Profit 2,275 63.784 +3,466.7 557.814
Earnings Per Share () 0.9373 0.0287 +3,165.9 0.2570
Dividend Per Share () 0.0000 0.0000 N/A 0.0000
Announcement Date 2023-08-21 2022-08-31 NA 2021-08-26
* Annualised
Last Update Time: 2024-03-02 21:40:28
Back to Top